Cefiderocol versus high-dose, extended-infusion meropenem for the treatment of Gram-negative nosocomial pneumonia (APEKS-NP): a randomised, double-blind, phase 3, non-inferiority trial

Authors: Richard G. Wunderink, Yuko Matsunaga, Mari Ariyasu, Philippe Clevenbergh, Roger Echols, Keith S. Kaye, Marin H. Kollef, Anju Menon, Jason M. Pogue, Andrew F. Shorr, Jean‐François Timsit, Markus Zeitlinger, Tsutae Den Nagata - The Lancet 2020 cited by 464